Order Article Reprints

Signorelli C, Calegari MA, Basso M, Anghelone A, Lucchetti J, Minelli A, Angotti L, Zurlo IV, Schirripa M, Chilelli MG, et al. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study. Current Oncology. 2023; 30(6):5456-5469. https://doi.org/10.3390/curroncol30060413

Signorelli, Carlo, Maria Alessandra Calegari, Michele Basso, Annunziato Anghelone, Jessica Lucchetti, Alessandro Minelli, Lorenzo Angotti, Ina Valeria Zurlo, Marta Schirripa, Mario Giovanni Chilelli, and et al. 2023. "Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study" Current Oncology 30, no. 6: 5456-5469. https://doi.org/10.3390/curroncol30060413

Signorelli, C., Calegari, M. A., Basso, M., Anghelone, A., Lucchetti, J., Minelli, A., Angotti, L., Zurlo, I. V., Schirripa, M., Chilelli, M. G., Morelli, C., Dell’Aquila, E., Cosimati, A., Gemma, D., Ribelli, M., Emiliani, A., Corsi, D. C., Arrivi, G., Mazzuca, F., ... Ruggeri, E. M. (2023). Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study. Current Oncology, 30(6), 5456-5469. https://doi.org/10.3390/curroncol30060413